← Signal Board

VistaGen Therapeutics financial statements

비스타젠 테라퓨틱스NASDAQ:VTGN · Nasdaq · Healthcare · sector #20
$0.2462-0.36%
2026-10-08 close

VistaGen Therapeutics's published financial data is dated 2026-10-04. 2025 revenue was $0M. 2025 operating profit was −$56M.

Reported results

Financial safety

Reference indicatorAs of 2025
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -9.52
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-9.52
Beneish M-Score
-4.16

No statistical flag

Sloan accrual
-11.05%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

1/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score1/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -8662%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-3103.5% → -11517.1%, -8413.6%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-11,517.1%
Interest coverage
-12.3x
Return on equity (ROE)
-73%

Operating margin −5pp

Operating loss
Interest coverageBase -12.3x adverse case -12.3x
Return on equity (ROE)Base -73% adverse case -86%

Revenue −15%

Interest coverage risk
Interest coverageBase -12.3x adverse case -10.4x
Return on equity (ROE)Base -73% adverse case -74.1%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -12.3x adverse case -11.6x
Return on equity (ROE)Base -73% adverse case -86.4%

Interest coverage limit

Already below the limit by 12,454.3pp

Interest coverage limit at an operating margin of 937.2%

Interest expense coverage threshold

VistaGen Therapeutics notifications

Quantus Signal · live data · not investment advice · Privacy Policy